Digital QbD: The Role of Artificial intelligence in Modern Drug Development

Miss. Tisha F Patel[1]
Research Scholar Sat Kaival College of Pharmacy, Sarsa[1]

I. **ABSTRACT:** Artificial intelligence (AI) has become a revolutionary technology in the pharmaceutical sector, providing innovative solutions that improve the precision, efficiency, and dependability of quality assurance (QA) activities. The integration of AI within the QbD approach has reshaped pharmaceutical development by enhancing precision, productivity and innovative capabilities. Digital Quality by Design and Artificial Intelligence are revolutionizing drug development by transitioning from traditional, empirical, trial-and-error methods to data-driven predictive and accelerated, in silico processes. In recent years, advances in computational pharmaceutics have provided a new methodological foundation for drug development. To demonstrate the practical applications of QbD, two representative examples are discussed: a virtual development workflow for amorphous solid dispersions based on QbD principles, and real-world case involving the design of long- acting in situ gel injectables. AI technologies are now broadly implemented throughout major stages of the drug discovery pipeline, such as identifying therapeutic targets, discovering and optimizing lead compounds, repurposing existing drugs, and predicting toxicity. AI-driven systems like AlphaFold have revolutionized protein structure prediction, greatly advancing our understanding of molecular behaviour.

KEYWORDS: Artificial intelligence, QbD, Pharmaceutical Drug Development, Digital QbD

[1] INTRODUCTION:

As a producer of lifesaving drugs with direct impact on global healthcare outcomes, the pharmaceutical manufacturing industry demands continuous innovation, uncompromising safety standards, and precision in all operations. Digital Quality by Design (Digital QbD) is the evolution of traditional Quality by Design (QbD) principles using advanced digital technologies such as artificial intelligence (AI), machine learning (ML), big data analytics, and digital twins. By using machine learning models, AI helps accurately identify the key material characteristics and critical process parameters that truly affect product quality. This allows developers to understand which variables matter most and how they interact, instead of relying mainly on repeated experimental trial-and-error. As a result, development becomes more efficient, data-driven, and scientifically precise, with fewer unnecessary experiments. By mapping out a “Design Space”- a range of conditions where quality is assured- QbD creates a roadmap for consistent production.

Global adoption of AI in Pharmaceutical manufacturing is in line with more general regulatory goals established by an organization like European Medicines Agency and the U.S. Food and Drug Administration (FDA), which both support automation and data integrity for improved quality assurance.

AI is an ideal way to manage the huge amounts of data generated during operations, especially since modern pharmaceutical manufacturing is highly complex and demands precision, strict quality control, and full compliance with regulations. It also helps in the preclinical trials of the experimental drugs.

[2] QUALITY BY DESIGN: A FUNDAMENTAL CONCEPT:

2.1 Product Quality Lifecycle Approach:

The product quality life cycle approach highlights that quality should be integrated into a drug right from the initial development stages and maintained throughout commercialization and even after it reaches the market. This principle starts with defining the target product profile (TPP) delineates the expected characteristics of the drug, including its dosage form, strength, and therapeutic effects. Quality by Design (QbD) is a methodical approach to pharmaceutical development and manufacture that prioritizes the comprehension and regulation of processes to guarantee uniform product quality. The use of artificial intelligence (AI) into Quality by Design (QbD) methodologies can markedly improve the efficiency, efficacy, and resilience of quality assurance procedures.

2.2 Risk based Approach:

QbD priorities risk management, recognizing that not all variables in drug development carry equal weight. A risk-based approach means recognizing, evaluating, and controlling any factors that might negatively affect the quality of the product. Developers evaluate the potential risks such as an unstable active ingredient or inconsistent manufacturing process and rank them based on their impact and likelihood.

[3] AI IN DRUG DISCOVERY:

Drug discovery is a complex and time-consuming process that usually takes about 10 to 15 years. It begins with identifying new biological targets that can help treat a particular disease. After that, high-throughput screening (HTS) is used to test large libraries of compounds to find potential candidates that can act on those targets. The selected compounds are then optimized to enhance their drug-like properties. Finally, these candidates go through detailed preclinical studies, clinical trials, and regulatory review before they can be approved for use. A typical drug discovery pipeline consists of multiple stages. The initial phase involves identifying new targets that demonstrate a connection to a particular disease. Next, compounds that potentially interact with these targets are discovered through high-throughput screening (HTS) of compounds libraries. These compounds are then optimized to enhance their drug-like properties.

The key roles of AI are:

1. Target Identification and validation: AI analyses large biological datasets (genomics, proteomics, transcriptomics) to identify potential drug targets and understand disease mechanisms more precisely.

2. Virtual Screening and Hit Identification: Machine learning models can screen millions of compounds computationally to predict which molecules are most likely to bind to a target, reducing the need for extensive laboratory high-throughput screening (HTS).

3. Prediction of ADMET Properties: AI models predict Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) early in development, helping eliminate unsuitable candidates before costly trials.

4. Drug Design and Optimization: AI helps design new molecules and optimize lead compounds by predicting properties such as potency, selectivity, solubility, and toxicity. Generative models can even create novel chemical structures with desired characteristics.

5. Clinical Trial Optimization: AI assists in selecting suitable patient populations, predicting outcomes, monitoring safety, and improving trial design, increasing the chances of success.

6. Reducing Time and Cost: By improving efficiency at many stages of drug discovery, it significantly reduces the overall time and money waste.

Figure 1. Generative AI in drug discovery

[4] AI Applications in QBD for Pharmaceutical Formulation:

4.1 Formulation Optimization:

A. Identification of Critical Quality Attributes (CQAs):

AI analyses historical formulation and process data to identify and prioritize CQAs that significantly affect product quality, such as dissolution rate, stability, and bioavailability.

B. Risk Assessment and Critical Material Attributes (CMAs) Selection:

Machine learning models help evaluate the impact of raw material properties and process parameters on final product performance, enabling better identification of CMAs and Critical Process Parameters (CPPs).

C. Design of Experiments (DoE) Optimization:

AI enhances traditional DoE by predicting outcomes from fewer experiments. It can suggest optimal experimental combinations, reducing time and material consumption.

D. Formulation Prediction and Optimization:

AI models predict how changes in excipient concentration, processing conditions, or formulation composition affect drug release and stability, helping researchers achieve optimal formulations faster.



Figure 2. Application of AI

4.2 Predictive modelling for Drug Release and Stability:

AI enhances QbD by predicting drug release profile physicochemical stability. Machine learning model analyses datasets encompassing characteristics of drugs, formulation specification and environmental factors to forecast CQAs like dissolution rates and shelf-life-stability. For example, MIT researchers developed an AI model to predict drug release from polymer-based delivery systems, enabling controlled release formulations for diabetes medications that Improve the patient compliance.

4.3 Personalized Medicines and 3D Printing:

AI enhances the Quality by Design (QbD) approach in the development of personalized medicines by adjusting formulations according to individual patient characteristics such as age, body weight, and medical history. In the case of 3D-printed dosage forms, AI algorithms help design customized drug release patterns and dosage geometries to improve treatment effectiveness. This strategy supports QbD's objective of fulfilling patient requirements through precise and targeted product design.

[5] <u>BENEFITS OF AI IN DRUG DISCOVERY</u>: Incorporating AI into its production and quality assurance procedures can yield numerous benefits for the medical device sector, significantly enhancing productivity, reliability, and quality.



Figure 3. Benefits of AI in Drug discovery

- **Faster time-lines:** AI can analyse massive biological datasets to quickly identify potential of drug targets. For example,

DeepMind's protein-structure prediction system accelerated structural biology research.

AlphaFold predicted millions of protein structures in a fraction of the time traditional lab methods require.

- **Reduced costs:** Artificial intelligence (AI) reduces costs in drug discovery by minimizing trial-and-error experimentation, lowering failure rates, and shortening development timelines. Traditionally, developing a single drug can cost over $1–2 billion, with a large portion of expenses coming from failed candidates in late-stage clinical trials. AI helps identify promising drug targets, predict toxicity, and optimize compounds early in the process, reducing the likelihood of costly failures. Technologies such as AlphaFold developed by DeepMind decrease the need for expensive laboratory experiments, while companies like Insilico Medicine use AI to virtually screen and design drug candidates more efficiently.
- **Increased Success Rate:** Artificial intelligence (AI) increases the success rate in drug discovery by improving the accuracy, precision, and efficiency of decision-making throughout the development pipeline. One of the biggest challenges in traditional drug development is the high failure rate, especially during costly clinical trials. AI helps address this by identifying more reliable drug targets through large-scale analysis of genomic and biological data, improving early target validation. For example, tools like AlphaFold developed by DeepMind enhance understanding of protein structures, allowing researchers to design drugs that better bind to their intended targets.

- **Personalized Medicines:** Artificial intelligence (AI) plays a crucial role in advancing personalized medicine within drug discovery by tailoring treatments to individual patients rather than using a one-size-fits-all approach. AI can analyse vast amounts of genomic, clinical, and lifestyle data to identify patient subgroups that are more likely to respond to specific therapies. For example, research initiatives such as the UK Biobank provide large-scale health and genetic data that AI systems use to uncover patterns linked to disease risk and treatment response. This enables the development of targeted therapies designed for specific genetic profiles.

- **Drug Repurposing:** AI significantly enhances drug repurposing in drug discovery by identifying new therapeutic uses for existing drugs by the people , saving time costs and resources compared to developing entirely new compounds. Traditional repurposing relies on serendipity or slow manual analysis, whereas AI can rapidly analyse vast datasets including molecular structures, genomic profiles, clinical trial results, and real-world patient data to uncover hidden connections between drugs and diseases.

For example, BenevolentAI used AI to identify existing compounds with potential efficacy against COVID-19, accelerating the discovery of treatment candidates. AI models can predict drug-target interactions, anticipate side effects, and prioritize the most promising candidates for further testing.

[6] CHALLENGES AND ETHICAL CONSIDERATION:

The use of AI in pharmaceutical manufacturing offers significant promise, but it also faces many challenges. One of the biggest issues is the lack of standardization and reliable data. Manufacturing information is often scattered across outdated legacy systems, making it difficult to integrate and scale AI technologies effectively.

Digital QbD requires large amounts of high-quality data from multiple sources such as laboratory systems, manufacturing equipment, and quality control databases. However, these data are often stored in different formats and legacy systems, making integration and standardization difficult.

Pharmaceutical industries must comply with strict regulatory guidelines from organizations like U.S. Food and Drug Administration and European Medicines Agency. Ensuring that digital QbD systems meet regulatory requirements and maintain proper documentation can be complex.

Cybersecurity is an additional issue. Vulnerabilities grow with the interconnectedness of manufacturing systems, increasing the likelihood of ransomware attacks, data breaches, and unauthorized data manipulation. Protecting sensitive pharmaceutical
data requires adherence to ISO/IEC 27001 and other cybersecurity standards.

To ensure ethical and legal compliance, AI models should be transparent, unbiased, and easily traceable. Another important challenge is adapting the workforce. As manufacturing increasingly adopts digital technologies, workers must develop new skills in data science, automation, and AI-based analysis. If proper training and coordination are not provided, the interaction between humans and machines may create difficulties rather than improving efficiency.

[7] FUTURE TRENDS AND DEVELOPMENTS:

AI has a bright future in the pharmaceutical sector, with the ability to completely transform PMS, industry management, regulatory affairs, drug discovery, and pharmaceutical product development. Large volumes of biological data can be analysed by AI algorithms to find possible therapeutic targets and speed up the drug discovery process. Drug research can use AI-driven simulations to forecast how chemicals will interact with biological systems, enabling more effective and economical clinical trials. Artificial intelligence (AI) solutions can also advance supply chain management, strengthen regulatory compliance, and allow manufacturing and formulation development to move forward more quickly. AI algorithms demand large libraries of data and information. The evolution of AI technology into the pharma sector will cultivate innovations, improve patient outcomes, and ultimately disrupt health care in an ever-changing technological society.

AI technology is anticipated to improve quality control standards and support more dependable decision-making. As intelligent manufacturing systems continue to advance, factories are likely to operate with greater independence, leading to higher flexibility and responsiveness in production. These smart factories will apply AI to optimize operations, minimize waste, and quickly adjust to changing customer demands.

Future medical device smart factories are expected to have sophisticated autonomous features. This transformation will make Production processes more agile and adaptable. Manufacturers can construct responsive and adaptive production environments that swiftly respond to new information and adjust operations by integrating AI with cutting-edge technologies, such as machine learning and the Internet of Things (IoT).

Figure 4. Future trends of AI

[8] CONCLUSION:

Digital Quality by Design (QbD) supported by artificial intelligence represents a transformative approach in modern drug development. The integration of AI with QbD principles enables more efficient data analysis, improved process understanding, and enhanced prediction of critical quality attributes. Also digital QbD helps the manufacturing industries by reducing time of the drug development process and money expenditure. By utilizing advanced computational tools, pharmaceutical scientists can optimize formulations and manufacturing processes with greater accuracy and speed. Furthermore, AI-driven digital QbD frameworks support real-time monitoring, risk assessment, and data-driven decision-making throughout the product lifecycle. This approach not only improves product quality and consistency but also reduces development time, cost, and resource utilization. Overall, the adoption of AI within digital QbD is expected to accelerate innovation, strengthen regulatory compliance, and play a vital role in shaping the future of modern pharmaceutical development.

[9] REFERENCES:

1. Priyankkumar Patel, "Impact of AI on Manufacturing and Quality Assurance in Medical Devices and Pharmaceutical Industry", International Journal of Innovative Technology and Exploring Engineering, 2024, Volume-13, Pg no.: 18

2. Shayari Dutta, Tapan Kumar Chaudhuri, "Artificial Intelligence and Machine Learning- Driven Pharmaceutical Industry", International Journal of Current Science Research and Review, 2025, Volume-08, Pg no.: 2124

3. Palavan Krishna, Nagarajan Janki Sankarachari Krishnan, Anamika Dey, Shenthilanathan, Sivakumar, Sarvesh Ravichandran, Mullaiadhavan Bharathi, "Tech-Driven Trust: The Role of AI and Emerging Technologies in Pharmaceutical Quality Assurance", International Journal of Applied Pharmaceutics, 2025, Volume-17, Pg no.: 122-123

4. Ganji Pramod Sambamoorthi, Dr. Pabba Parameshwar, "Assessing the Role of AI in Revolutionizing Pharmaceutical Quality Assurance Systems for Faster and Accurate Regulatory Compliance", International Journal of Innovative Research Technology, 2025, Volume-11, Pg no.: 916

5. Prof. (Dr.) Mohd. Wasiullah, Prof. (Dr.) Piyush Yadav, Archna Chauhan, Pritee Yadav, "The Role of Artificial Intelligence in Modern Manufacturing of the Pharmaceutical Industry" International journal of Innovative Research in Technology, 2025, Volume-12, Pg no.: 4069

6. M. A. Sujan, S. White, I. Habli, and N. Reynolds, "Stakeholder perceptions of the safety and assurance of artificial intelligence in healthcare," Safety Science, volume. 155, p. 105870, 2022.

7. Mohd. Wasiullah, Dr. Piyush Yadav, Pooja Yadav, "The Role of AI Quality Control and Assurance: Present and Future Perspectives", International journal of Innovative Research in Technology, 2025, Volume-12, Pg no.:4072-4074

8. Rantanen J, Khinast J. "The Future of Pharmaceutical Sciences. J Pharm Sci.2015;104(11):3612-38

9. Patel Mehul, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar, Ekta Patel, AI-Enable Quality by Design in Pharmaceutical Formulation, International Journal of Technology. 2025; 15(2):75-81.

10. https://www.mdpi.com/1999-4923/16/10/1328

11. https://www.linkedin.com/pulse/artificial-intelligence-quality-design-nallan-chakravarthy-madhu-qmvpc

12. https://www.solulab.com/generative-ai-in-drug-discovery/

13. https://www.slideshare.net/slideshow/artificial-intelligence-in-drug-discovery-and-development/240130022